Daiichi Sankyo Names Global Head, Oncology R&D

From DCAT Value Chain Insights (VCI)

By People On The Move posted 04-12-2016 15:06


Daiichi Sankyo, Inc. has appointed Antoine Yver, MD, MSc, to Global Head, Oncology Research and Development, effective April 1, 2016.

In this newly created role, Dr. Yver will report to Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head, Research & Development, Daiichi Sankyo Co., Ltd. and Chairman of the Board and President, Daiichi Sankyo, Inc., and will have responsibility for leading all of the global research and development across the oncology therapeutic area including external investments, internal pipeline decisions, and resourcing requirements .

Dr. Yver joins Daiichi Sankyo from AstraZeneca, where he most recently served as Senior Vice President and Head of Oncology, Global Medicines Development, and Global Medicines Development China Lead across all therapeutic areas. Prior to joining AstraZeneca in 2009, he held several international oncology drug development positions at Merck/Schering-Plough, Johnson & Johnson and Rhône-Poulenc Rorer/Aventis.

Source: Daiichi Sankyo


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription